English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Community Oncology Alliance
+
Regulatory
H. P. Barber
| Jul 15, 2026
Community Oncology Alliance executive director: 340B program has become 'the picture of waste and abuse'
+
Regulatory
K. O. Breen
| Jul 9, 2026
Community Oncology Alliance: '340B should support patients, not large hospital systems'
+
Regulatory
A. B. Adkins
| Jul 6, 2026
COA executive director: '340B dollars are meant for patients in need, not corporate profits'
+
Regulatory
Patient Daily
| May 14, 2026
Community Oncology Alliance Executive Director Okon on 340B program: 'Hospitals and their CEOs rake in the profits while patients in need go without'
+
Regulatory
Patient Daily
| May 4, 2026
Community Oncology Alliance Exec. Director on PBMs: 'The top PBMs are the scourge of society'
+
Pharmaceuticals
Patient Daily
| Jul 21, 2025
Executive director of COA on 340B abuse: ‘Imagine using cancer patients as a source of revenue’
+
Pharmaceuticals
Patient Daily
| May 29, 2025
Executive director of COA on 340B reform: ‘Start with PBMs then mega hospitals that pocket 340B discounts’
+
Regulatory
Vimbai Chikomo
| Apr 26, 2016
Expert: CMS’ proposed change to Medicare Part B may reverse progress in cancer care
Trending
+
Pharmaceuticals
Patient Daily
| Aug 4, 2026
Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+
Pharmaceuticals
Patient Daily
| Aug 6, 2026
FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+
Regulatory
M. R. Armstrong
| Aug 4, 2026
Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+
Pharmaceuticals
Patient Daily
| Aug 5, 2026
Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes
